The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 39.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 38.70
Low: 38.70
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New distribution agreement signed

7 Jul 2014 07:00

RNS Number : 5540L
Venture Life Group PLC
07 July 2014
 



 

 

 

Venture Life Group plc

("Venture Life" or "the Group")

New distribution agreement signed with existing partner

 

Bracknell, UK - 7 July 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that it has signed a second long-term distribution agreement with an existing partner for the distribution rights to NeuroAge™ NRG and NeuroAge™ Sleep, the Group's two new line extensions for the NeuroAge™ range.

 

The agreement has been signed with Elpen who already own the distribution rights to NeuroAge™ in Greece and who launched NeuroAge™ in Greece in 2013. Market launch of NeuroAge™ NRG and NeuroAge™ Sleep in Greece is expected in Q1 2015.

 

This follows the announcement on 25 June 2014 that the Group had signed its first distribution agreement for NeuroAge™ NRG and NeuroAge™ Sleep with another existing partner, MedMen, covering distribution of the products in Romania and Moldova.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted that Elpen has signed a further distribution agreement for the two new line extensions to NeuroAge. The signing of this agreement by Elpen is not only an endorsement of our product development strategy but it also reflects the strong start that NeuroAge has achieved in Greece since its market launch."

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742870

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

JW Communications

Julia Wilson +44 (0) 7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population.

 

The Group's range of branded products currently includes food supplements for maintaining brain function, dermatology products for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners. The Group's own branded products are currently sold or partnered in over 40 countries.

 

The Group also has a healthy new product development pipeline including products in areas such as cholesterol reduction, diabetes, cardiovascular health, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and dermatology sectors.

 

 

About NeuroAge™

NeuroAge™ is a food supplement formulated to help support alertness, cognitive function and mental performance in a healthy brain. The key components have been extensively studied and these studies show their action in supporting cognitive function.

 

About NeuroAge™ NRG and NeuroAge™ Sleep

NeuroAge™ NRG and NeuroAge™ Sleep are new additions to the NeuroAge™ range. As well as supporting cognitive function, NeuroAge™ NRG has been specially formulated to maintain alertness and NeuroAge™ Sleep helps to promote sleep and reduce the time taken to fall asleep.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUSONRSSABRAR
Date   Source Headline
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company
10th Dec 20204:45 pmRNSHolding(s) in Company
10th Dec 20204:41 pmRNSHolding(s) in Company
10th Dec 20202:42 pmRNSHolding(s) in Company
10th Dec 20201:45 pmRNSHolding(s) in Company
9th Dec 20202:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.